WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 462483
CAS#: 916603-07-1
Description: CZC-8004 is a pan-kinase inhibitor and binds a range of tyrosine kinases, including ABL kinase.
MedKoo Cat#: 462483
Name: CZC-8004
CAS#: 916603-07-1
Chemical Formula: C17H16FN5
Exact Mass: 309.139
Molecular Weight: 309.3484
Elemental Analysis: C, 66.01; H, 5.21; F, 6.14; N, 22.64
Synonym: CZC-8004; CZC8004; CZC 8004
IUPAC/Chemical Name: N2-(4-(aminomethyl)phenyl)-5-fluoro-N4-phenylpyrimidine-2,4-diamine
InChi Key: UKOHFWNBTUJMMN-UHFFFAOYSA-N
InChi Code: InChI=1S/C17H16FN5/c18-15-11-20-17(22-14-8-6-12(10-19)7-9-14)23-16(15)21-13-4-2-1-3-5-13/h1-9,11H,10,19H2,(H2,20,21,22,23)
SMILES Code: NCC1=CC=C(NC2=NC=C(F)C(NC3=CC=CC=C3)=N2)C=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 309.3484 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Deane FM, Lin AJS, Hains PG, Pilgrim SL, Robinson PJ, McCluskey A. FD5180, a Novel Protein Kinase Affinity Probe, and the Effect of Bead Loading on Protein Kinase Identification. ACS Omega. 2017;2(7):3828-3838. doi:10.1021/acsomega.7b00020
2: Bantscheff M, Eberhard D, Abraham Y, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol. 2007;25(9):1035-1044. doi:10.1038/nbt1328
